Theragen receives US patent for spinal fusion bone growth stimulator
Click Here to Manage Email Alerts
Theragen has announced the issuance of a second U.S. patent for its ActaStim-S, a wearable and app-compatible postoperative bone growth stimulator for patients undergoing spinal fusion, according to a release.
The ActaStim-S device, a wearable which can be connected to the Sync app, helps patients undergoing spinal fusion track their usage, activity levels and pain entry reporting, according to the release.
“Receiving the patent is important. It's also validating seeing the ActaStim-S design so well received by patients and surgeons,” Chris McAuliffe, CEO of Theragen, said in the release. “Our first patent focused on device connectivity, while this patent protects our device design. ActaStim-S offers significant practical advantages [vs.] large, obtrusive devices that can constrain ambulation and mobility. ActaStim-S remains the innovation leader compared to devices that do not track compliance and activity levels, communicate, or engage patients toward therapeutic compliance. Patients and surgeons expect medical devices to collect and process data, to be digitally connected, ultra-modern and easy to use for all ages and lifestyles. Our device design delivers proven therapy at home, at work or on the go; for modern times and high expectations,” McAuliffe added.
Read more about
Click Here to Manage Email Alerts